Literature DB >> 16047736

A correlation between the heterogeneity of hypervariable region 1 of E2 glycoprotein of Hepatitis C virus (HCV) and HCV antibody profile: a case study.

D Kmieciak1, J Biernacka-Lukanty, P Migdalski, J Turek-Plewa, A Wierzbicki, J Juszczyk, W H Trzeciak.   

Abstract

A correlation between the heterogeneity of hypervariable region 1 (HVR1) of E2 glycoprotein (gp) and Hepatitis C virus (HCV) antibody profile was investigated. Of 6 patients studied two were in acute phase, two in chronic phase and two showed signs of long-time HCV infection, i.e. liver cirrhosis. All the patients exhibited a vigorous antibody response to viral proteins C, NS3, NS4 and NS5. An antibody response to HVR1 of E2 was found in one patient in acute phase and in one or two patients in chronic phase. Such a response was not found in the two patients with liver cirrhosis. Single-stranded conformation polymorphism (SSCP) and sequence analyses of HVR1 of E2 showed the lowest HVR1 heterogeneity in patients in acute phase and the highest one in those in chronic phase, while the long-time carriers of the virus showed an intermediate heterogeneity. This may reflect a specific interplay between the virus and immune system. The HVR1 heterogeneity may rise in the course of infection as a means of evading the immune pressure. Then, when an organism is unable to clear the virus, because the responses to HVR1 epitopes are weakened or exhausted, a population of less heterogeneous HVR1 variants may be established.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16047736

Source DB:  PubMed          Journal:  Acta Virol        ISSN: 0001-723X            Impact factor:   1.162


  2 in total

1.  Identification of a hepatitis C virus mutant lacking the hypervariable region 1 in a chronically infected patient non-responding to PEG-interferon-alpha/ribavirin therapy.

Authors:  D Kmieciak; P Migdalski; J Juszczyk; P P Jagodziński; W H Trzeciak
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-08-28       Impact factor: 3.267

2.  Application of a high-resolution melting technique for the rapid detection of partial replacement of HCV-1b by HCV-1a after PEG-IFNα/RBV therapy.

Authors:  M Holysz; K Bialas; P Migdalski; D Kmieciak; W H Trzeciak
Journal:  J Appl Genet       Date:  2014-11-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.